Coherus Declares Special Dividend of Contingent Value Rights Tied to Legacy Biosimilar Asset Sales
CHRS is trading near its 52-week low of $1.02 (14% above the low).
Summary
Coherus Oncology announced a special dividend of contingent value rights (CVRs) tied to the future sale or monetization of its legacy biosimilar assets. Stockholders of record on September 30, 2026 will receive one CVR per share, with potential cash payments over a two-year term ending October 7, 2028.
Key Events · Corporate Governance and Compliance · CHRS
-
Special Dividend of CVRs Declared
Board declared a dividend of one contingent value right (CVR) per share of common stock to stockholders of record as of September 30, 2026, with distribution on October 7, 2026.
-
CVRs Tied to Legacy BioSim Asset Sales
CVR holders will receive net cash proceeds from any sale, license, or royalty payments from the company's remaining biosimilar assets (patents, IP, cell lines, Pfizer royalty stream) during a two-year term ending October 7, 2028.
-
No Guaranteed Payment
CVRs are highly speculative; if no monetization occurs before expiration, they will expire worthless. The company's new $55M loan agreement with Innovatus restricts asset dispositions and CVR payments.
-
Investment Bank Retained for Sale Process
Company has engaged a capital markets adviser to assist with the sale of Legacy BioSim Assets, signaling intent to monetize these non-core assets.
Analysis · CHRS · Life Sciences
Coherus Oncology is distributing one contingent value right (CVR) per share to stockholders of record on September 30, 2026. The CVRs give holders the right to receive net cash proceeds from any sale, license, or royalty payments from the company's remaining biosimilar assets over a two-year term ending October 7, 2028. This is a shareholder-friendly move to unlock value from non-core assets while the company focuses on its oncology business. However, the CVRs are highly speculative — there is no guaranteed payment, and the company's new loan agreement with Innovatus restricts asset dispositions and CVR payments. The distribution itself does not dilute existing shareholders.
At the time of this filing, CHRS was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $177.7M. The 52-week trading range was $1.02 to $2.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.